Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Depreciation & Amortization (CF) (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Depreciation & Amortization (CF) for 7 consecutive years, with $7000.0 as the latest value for Q3 2025.

  • Quarterly Depreciation & Amortization (CF) changed 0.0% to $7000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $20000.0 through Dec 2025, down 92.51% year-over-year, with the annual reading at $267000.0 for FY2024, 48.05% down from the prior year.
  • Depreciation & Amortization (CF) hit $7000.0 in Q3 2025 for Harmony Biosciences Holdings, up from $6000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $164000.0 in Q4 2023 to a low of $6000.0 in Q4 2024.
  • Historically, Depreciation & Amortization (CF) has averaged $86105.3 across 5 years, with a median of $100000.0 in 2021.
  • Biggest YoY gain for Depreciation & Amortization (CF) was 58.25% in 2024; the steepest drop was 96.34% in 2024.
  • Year by year, Depreciation & Amortization (CF) stood at $117000.0 in 2021, then fell by 8.55% to $107000.0 in 2022, then surged by 53.27% to $164000.0 in 2023, then tumbled by 96.34% to $6000.0 in 2024, then rose by 16.67% to $7000.0 in 2025.
  • Business Quant data shows Depreciation & Amortization (CF) for HRMY at $7000.0 in Q3 2025, $6000.0 in Q2 2025, and $7000.0 in Q1 2025.